The Critical Gap in Ethnicity Reporting Exposed by New Research

New Zealand's clinical research landscape faces a significant challenge: many clinical trials are not adequately capturing or reporting participants' ethnicity data. A groundbreaking systematic review published in the New Zealand Medical Journal on January 30, 2026, has brought this issue to light, analyzing randomized controlled trials (RCTs) conducted in the country over a decade. This research, led by a team from the Medical Research Institute of New Zealand (MRI) with ties to Te Herenga Waka—Victoria University of Wellington, reveals that nearly 30% of trials failed to report any ethnicity information at all. For those that did, the data was often inconsistent, non-standardized, and riddled with categories that don't align with national standards, leaving a whopping 70.6% of participants unclassifiable under Stats New Zealand (Stats NZ) level one ethnicity codes.

This oversight hampers efforts to ensure equitable representation in clinical trials, particularly for Māori and Pacific peoples who experience disproportionate health burdens. In Aotearoa New Zealand, upholding Te Tiriti o Waitangi principles of partnership, protection, and participation demands better data to track progress toward health equity. Without it, treatments developed through these trials may not translate effectively across diverse populations, perpetuating disparities.

Decoding the Systematic Review: Methods and Scope

The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, with its protocol preregistered on PROSPERO (CRD42020210764). Researchers scoured the Australia New Zealand Clinical Trials Registry (ANZCTR) for interventional RCTs registered between October 12, 2010, and October 12, 2020, that were completed, ethically approved, and linked to a PubMed publication. From 1,040 identified trials, 342 met the criteria after dual screening by independent reviewers.

Key data extracted included trial phase, funding source, sponsor type, and ethnicity details from publications. Ethnicity was mapped to Stats NZ Tatauranga Aotearoa level one categories: European, Māori, Pacific peoples, Asian, Middle Eastern/Latin American/African (MELAA), and Other. A 'residual' category captured mismatches like 'White', 'non-Hispanic', or vague free-text entries. This rigorous approach highlighted not just absence but also poor quality of reporting.

Alarming Statistics: Underrepresentation and Data Chaos

Of the 342 trials, 103 (38%) omitted ethnicity data entirely, affecting transparency in participant demographics. The remaining 239 trials encompassed 295,254 participants, yet pooled proportions painted a stark picture: only 6.1% classified as European, 2.9% Māori, 1.4% Pacific peoples, 7.5% Asian, 2.5% MELAA, and 9.0% Other, with 70.6% residual. Compare this to the 2023 Census: 67.8% European, 17.8% Māori, 8.9% Pacific peoples—exposing gross underrepresentation of priority populations.

• 46.9% of trials labeled demographics as 'race'
• 39.7% used 'ethnicity'
• 13% both; definitions rarely aligned with Stats NZ standards

Mean per-study proportions showed slightly higher European (23.2%) but still dismal Māori (2.7%) and Pacific (1.8%) inclusion. Industry-sponsored trials dominated, potentially prioritizing speed over diversity.

Why Ethnicity Data is Essential in Clinical Trials

Ethnicity serves as a proxy for genetic, cultural, socioeconomic, and environmental factors influencing drug response, disease prevalence, and treatment outcomes. In New Zealand, Stats NZ's prioritized ethnicity system—self-identified, multiple responses allowed, hierarchically ordered—ensures consistency in health data collection. Yet, clinical trials lag, using incompatible terms like 'Caucasian' or binary 'race' categories.

Step-by-step, accurate capture involves: 1) Self-identification at recruitment; 2) Prioritization per Stats NZ (e.g., Māori before European if dual); 3) Recording all level one codes; 4) Reporting in protocols, ethics submissions, registries, and publications. Failure here risks biased results, where therapies safe for Europeans may harm others due to pharmacogenomic differences.

For researchers at universities like Victoria University of Wellington and the University of Auckland, this underscores the need for culturally responsive design from inception.

Health Disparities Fueling the Urgency for Change

Māori life expectancy lags by 7-10 years behind non-Māori, with higher rates of cardiovascular disease, diabetes, and cancer. Pacific peoples face similar inequities, compounded by urbanization and access barriers. Clinical trials must reflect this to validate interventions under Pūtātara—New Zealand's equity framework.

Historical mistrust from unethical studies like the 1980s cervical screening oversights erodes participation. Recent University of Auckland research highlights discrimination deterring Pacific Rainbow+ communities from healthcare altogether. Equitable trials could bridge these gaps, informing targeted policies.

Barriers to Diverse Recruitment in NZ Trials

Challenges include geographic isolation, especially rural Māori; cultural mismatches in consent processes; lack of iwi (tribal) engagement; and insufficient funding for community outreach. Health and Disability Ethics Committees (HDEC) require retrospective ethnicity breakdowns but optional fields misalign with Stats NZ.

Universities play pivotal roles: MRI's affiliation with Victoria University exemplifies integrated academic-clinical research. The University of Auckland's Te Kupenga Hauora Māori leads in responsive methodologies, advocating bias checks in ethnicity handling. Explore clinical research jobs to contribute to inclusive studies.